Shares of Insmed Inc. skyrocketed Tuesday, after the biopharmaceutical company said it plans to file a New Drug Application for its treatment of non-cystic fibrosis bronchiectasis following positive Phase 3 trial results.
Source: https://www.marketwatch.com/story/insme ... topstories
Insmed’s stock rockets toward a 2-decade high after positive drug-trial data
